Marker Diagnostics

Marker Diagnostics is a biotechnology company focused on developing objective molecular diagnostic tests for mild traumatic brain injury (mTBI), commonly known as concussion. The company's core technology utilizes a proprietary platform to identify and analyze specific salivary small non-coding RNA (sncRNA) biomarkers that change following a head impact. Their lead product, the Marker Concussion Test, is CE-marked and provides a biological tool to support clinical diagnosis and return-to-play decisions in sports and healthcare. By replacing subjective assessments with molecular data, Marker Diagnostics aims to enhance patient safety and long-term brain health management. The company maintains strong research ties with the University of Birmingham and collaborates with major sports organizations globally to validate its diagnostic solutions. This objective approach addresses a significant unmet need in neurology and sports medicine for reliable injury confirmation.